
Amphastar Pharma (AMPH) Stock Forecast & Price Target
Amphastar Pharma (AMPH) Analyst Ratings
Bulls say
Amphastar Pharma is being downgraded to a Hold due to concerns about top-line growth and the lack of near-term catalysts, as their next set of ANDA approvals and potential new products are not expected until 2027. The company's current focus is on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, as well as insulin API products, with a majority of their revenue coming from the United States.
Bears say
Amphastar Pharma is projected to face intense competition and slow growth potential due to the highly technical nature of its main products, including active pharmaceutical ingredients and insulin API products. Additionally, a significant portion of the company's revenue is heavily reliant on one product, which could lead to potential disruptions or declines in sales. Furthermore, the company's heavy reliance on its founders, who hold a significant percentage of the company's stock, creates potential concerns for corporate decision-making and control.
This aggregate rating is based on analysts' research of Amphastar Pharma and is not a guaranteed prediction by Public.com or investment advice.
Amphastar Pharma (AMPH) Analyst Forecast & Price Prediction
Start investing in Amphastar Pharma (AMPH)
Order type
Buy in
Order amount
Est. shares
0 shares